Bowles, D W <br/><br/>
Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).  [electronic resource] 

 -  Drugs of today (Barcelona, Spain : 1998)  Nov 2011 
 - 857-68 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1699-3993 
<br/><br/><label>Standard No.: </label>10.1358/dot.2011.47.11.1688487  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anilides--adverse effects<br/>Animals<br/>Antineoplastic Agents--adverse effects<br/>Clinical Trials as Topic<br/>Drug Interactions<br/>Drugs, Investigational--adverse effects<br/>Humans<br/>Neoplasms--drug therapy<br/>Proto-Oncogene Mas<br/>Pyridines--adverse effects<br/>Receptor Protein-Tyrosine Kinases--antagonists & inhibitors